Activity landscape analysis, CoMFA and CoMSIA studies of pyrazole CB1 antagonists

Medicinal Chemistry Research

Volumn 22, Issue 9, 2013, Pages 4133-4145

  Hernández Vázquez, Eduardo ^a   Méndez Lucio, Oscar ^a   Hernández Luis, Francisco ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

3D QSAR; Activity cliff; Cannabinoid receptor; CoMFA; CoMSIA; SAS maps

Indexed keywords

3 CARBONYL 4 METHYLPYRAZOLE; 3 CARBONYLPYRAZOLE; 4 METHYLPYRAZOLE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; HUMAN; METABOLIC SYNDROME X; MOLECULE; OBESITY; PHARMACOLOGICAL PARAMETERS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR BINDING; STRUCTURE ACTIVITY SIMILARITY;

EID: 84881119997     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0418-y     Document Type: Article

References (34)

1. Bajorath J, Peltason L, Wawer M, Guha R, Lajiness MS, Van Drie JH (2009) Navigating structure-activity landscapes. Drug Discov Today 14:698-705
2. Bays HE (2004) Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 12:1197-1211
3. Bifulco M, Grimaldi C, Gazezerro P, Pisanti S, Santoro A (2007) Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 71:1445-1456
4. Chen JZ, Han XW, Liu Q, Makriyannis A, Wang J, Xie XQ (2006) 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. J Med Chem 49:625-636
5. Cichero E, Menozzi G, Spallarossa A, Most L, Fossa P (2008) Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis. J Mol Model 14:1131-1145
6. Clapham JC, Arch JR, Tadayyon M (2001) Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 89:81-121
7. Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967
8. Durdagi S, Kapou A, Kourouli T, Andreou T, Nikas S, Nahmias VR, Papahatjis DP, Papadopoulos MG, Mavromoustakos T (2007) The Application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1′ position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2. J Med Chem 50:2875-2885
9. 2 cannabinoid receptors. J Med Chem 43:2300-2309
10. 2! J Mol Graph Model 20:269-276
11. Heifets A, Lilien RH (2010) LigAlign: flexible ligand-based active site alignment and analysis. J Mol Graph Model 29:93-101
12. Julien B, Grenarn P, Teixeira-Clerc F, Van Nhieu J, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S (2005) Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128:742-755
13. Kapetanovic IM (2001) Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact 171:165-176
14. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 7:4130-4146
15. Kubinyi H (1994) Variable selection in QSAR studies. I. An evolutionary algorithm. Quant Struct Act Relat 13:285-294
16. Kubinyi H (1997) QSAR and QSAR 3D in drug design part 1: methodology. Drug Discov Today 2:457-467
17. Lange JH, Coolen HK, van der Neut MA, Borst AJ, Stork B, Verveer PC, Kruse C (2010) Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism. J Med Chem 53:1338-1346
18. Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101-122
19. Maggiora GM (2006) On outliers and activity cliffs - why QSAR often disappoints. J Chem Inf Model 46:1535
20. Medina-Franco JL, Martínez-Mayorga K, Bender A, Marín RM, Giulianotti MA, Pinilla C, Houghten RA (2009) Characterization of activity landscapes using 2D and 3D similarity methods: consensus activity cliffs. J Chem Inf Model 49:477-491
21. Méndez-Lucio O, Pérez-Villanueva J, Romo-Mancillas A, Castillo R (2011) 3D-QSAR studies on purine-carbonitriles as cruzain inhibitors: comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). MedChemComm 2:1058-1065
22. Padwal RS, Majumdar SR (2007) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369:71-77
23. Pérez-Villanueva J, Santos R, Hernández-Campos A, Giulianotti MA, Castillo R, Medina-Franco JL (2010) Towards a systematic characterization of the antiprotozoal activity landscape of benzimidazole derivatives. Bioorg Med Chem 18:7380-7391
24. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosentock J (2009) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. J Am Med Assoc 295:761-775
25. Rücker C, Rücker G, Meringer M (2007) y-Randomization and its variants in QSPR/QSAR. J Chem Inf Model 47:2345-2357
26. Ruoxi L, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A (1999) Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42:769-776
27. Sisay MT, Petalson L, Bajorath J (2009) Structural interpretation of activity cliffs revealed by systematic analysis of structure-activity relationships in analog series. J Chem Inf Model 49:2179-2189
28. Smith RA, Fathi Z, Brown S, Choi S, Fan J, Jenkins S, Kluender HC, Konkar A, Lavoie R, Mays R, Natoli J, O'Connor SJ, Ortiz A, Podlogar B, Taing C, Tomlinson S, Tritto T, Zhang Z (2007) Constrained analogs of CB-1 antagonists: 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives. Bioorg Med Chem Lett 17:673-678
29. Stoit AR, Lange JH, Hartog AP, Ronken E, Tipker K, Stuivenberg HH, Dijksman JA, Wals HC, Kruse CG (2002) Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem Pharm Bull 50:1109-1113
30. Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrié P (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345-R353
31. Veselovsky AV, Ivanov AS (2008) Strategy of computer-aided drug design. Curr Drug Targets Infect Disord 3:33-40
32. WHO Infobase (2011) WHO Global Infobase: Infobase Home Page [WWW document]. http://www.who.int/infobase/report.aspx. Accessed 12 Nov 2011
33. Willett P, Barnard JM, Downs GM (1998) Chemical similarity searching. J Chem Inf Comput Sci 38:983-996
34. Zambre V, Murumkar P, Giridhar R, Ram Dayav M (2010) Development of highly predictive 3D-QSAR CoMSIA models for anthraquinone and acridone derivatives as telomerase inhibitors targeting G-quadruplex DNA telomere. J Mol Graph Model 29:229-239